CytoTools AG (T5O.DE)

0.5800 0.0000 (0.00%) At close: 05:36PM CEST

CytoTools AG

Darmstadt 64295
Germany

https://cytotools.de

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Mark-André Freyberg	Chief Executive Officer	N/A	N/A	N/A
Dr. Dirk Kaiser	Co-Founder & Chief Research Officer	N/A	N/A	N/A
Dr. Bruno Rosen	Member of Executive Board	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

bioXXmed AG, an investment company, invests in biotechnology or medical technology companies with equity or debt capital. It engages in the development of products for the diagnosis, alleviation, or cure of diseases through investments. The company was formerly known as CytoTools AG and changed its name to bioXXmed AG in September 2022. The company was founded in 2000 and is based in Darmstadt, Germany.

Corporate governance

CytoTools AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.